Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade Hemorrhoids

PHASE2CompletedINTERVENTIONAL
Enrollment

304

Participants

Timeline

Start Date

April 22, 2022

Primary Completion Date

April 20, 2023

Study Completion Date

May 17, 2023

Conditions
Hemorrhoids
Interventions
DRUG

Monad 1

Single therapy cream containing Lidocaine. Lidocaine is a topical anesthetic.

DRUG

Monad 2

Single therapy cream containing Halobetasol Propionate (low-strength). HPB is a topical corticosteroid.

DRUG

Monad 3

Single therapy cream containing Halobetasol Propionate (high strength).

DRUG

Combination - CITI-002 (low dose)

Combination cream containing Lidocaine and HBP (low)

DRUG

Combination - CITI-002 (high dose)

Combination cream containing Lidocaine and HBP (high)

Trial Locations (16)

17110

Site #04, Harrisburg

33409

Site #05, West Palm Beach

35801

Site #01, Huntsville

39503

Site #14, Gulfport

44060

Site #11, Mentor

49519

Site #02, Wyoming

68114

Site #08, Omaha

70433

Site #10, Covington

70769

Site #12, Prairieville

74133

Site #13, Tulsa

75070

Site #15, McKinney

85715

Site #07, Tucson

91767

Site #09, Pomona

91910

Site #06, Chula Vista

92103

Site #16, San Diego

92123

Site #03, San Diego

Sponsors
All Listed Sponsors
collaborator

Therapeutics, Inc.

INDUSTRY

lead

Citius Pharmaceuticals, Inc.

INDUSTRY

NCT05348200 - Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade Hemorrhoids | Biotech Hunter | Biotech Hunter